Leptin, its receptor and obesity

Journal of Investigative Medicine

Volumn 44, Issue 9, 1996, Pages 540-548

  Misra, Anoop ^a   Garg, Abhimanyu ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CELL SURFACE RECEPTOR; LEPTIN; LEPTIN RECEPTOR; PROTEIN;

ANIMAL; DISEASE MODEL; ENDOCRINE GLAND; ENERGY METABOLISM; GENETICS; HUMAN; HYPOTHALAMUS; MOUSE; MOUSE MUTANT; MUTATION; OBESITY; PHYSIOLOGY; REVIEW;

ANIMALS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ENDOCRINE GLANDS; ENERGY METABOLISM; HUMANS; HYPOTHALAMUS; LEPTIN; MICE; MICE, OBESE; MUTATION; OBESITY; PROTEINS; RECEPTORS, CELL SURFACE;

EID: 0030331944     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The national health and nutrition examination surveys, 1960 to 1991. JAMA 1994;273(3):205-11.
2. Pan American Health Organization. Annual report from the Pan American Health Organization: health in Americas. Washington, DC: Pan American Health Organization, 1987.
3. Mata L, Rosero L. National health and social development in Costa Rica: a case study of intersectoral action. Washington, DC: Pan American Health Organization, 1988.
4. Bouchard C. The genetics of obesity. Boca Raton: CRC Press, 1994.
5. Oomura Y. Central mechanism of feeding. In: Katoni M, ed. Advances in biophysics. Tokyo: Tokyo University Press, 1973:65-142.
6. Bray GA, Campfield LA. Metabolic factors in the control of energy stores. Metabolism 1975;24:99-117.
7. Bray GA, Sclafani A, Novin D. Obesity-inducing hypothalamic knife cuts: effects on the lipolysis and blood insulin levels. Am J Physiol 1982;23:R445-9.
8. Axen KV, Li X, Fung K, Sclafani A. The VMH-dietary obese rat: a new model of non-insulin dependent diabetes mellitus. Am J Physiol 1994;266:R921-8.
9. Shimazu T. Reciprocal innervation of the liver: its significance in metabolic control, In: Szabo AJ, ed. Advances in metabolic disorders, CNS regulation of carbohydrate metabolism. New York: Academic Press, 1983;10:55-84.
10. Jeanrenaud B, Halimi S, Van de Werve G. Neuroendocrine disorders seen as triggers of the triad: obesity-insulin resistance-abnormal glucose tolerance. Diabetes Metab Rev 1985;1:261-91.
11. Leibowitz SF. Brain neuropeptide Y: an integrator of endocrine, metabolic, and behavioral processes. Brain Res Bull 1991;27:333-7.
12. Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero D, O' Donohue TL. The anatomy of neuropeptide Y containing neurons in the rat brain. Neuroscience 1985;15:1159-81.
13. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984;115:427-9.
14. Morley JE, Levine AS, Gosnell BA, Kneip J, Grace M. Effects of neuropeptide Y on ingestive behaviors in the rat. Am J Physiol 1987;252:R599-609.
15. Paez X, Myers RD. Insatiable feeding evoked in rats by recurrent perfusion of neuropeptide Y in the hypothalamus. Peptides 1991;12:609-16.
16. Egawa M, Yoshimatsu H, Bray GA. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue. Am J Physiol 1991;260:R328-34.
17. Vettor R, Zarjevski N. Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B. Induction and reversibility of an obese syndrome by intraventricular neuropeptide Y administration to normal rats. Diabetologia 1994;37:1202-8.
18. Dryden S, Frankish H, Wang Q, Williams G. Neuropeptide Y and energy balance: one way ahead for the treatment of obesity. Eur J Clin Invest 1994;24:293-308.
19. Eva C, Kreinanene K, Monyer H, Seeburg P, Sprengel R. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett 1990;271:80-4.
20. Leibowitz SF. Brain monoamines and peptides: role in the control of eating behavior. Fed Proc 1986;45:1396-403.
21. Arase K, Shargill NS, Bray GA. Effects of intraventricular infusion of corticotropin-releasing factor on VMH-lesioned obese rats. Am J Physiol 1989;256:R751-6.
22. Rohner-Jeanrenaud F, Walker CD, Greco-Perotto R, Jeanrenaud B. Central corticotropin-releasing factor administration prevents the excessive body weight gain of genetically obese (fa/fa) rats. Endocrinology 1989;124:733-9.
23. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insularaxis. Diabetologia 1992;35:701-11.
24. Turton MD, O'Shea D, Gunn I, Beak SI, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
25. Vanderhaeghen JJ, Signeau JC, Gepts W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 1975;257:604-5.
26. Dockray GJ. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 1976;264:568-70.
27. Dourish CT, Smithe GP, Gibbs J. The development and proof of the CCK hypothesis of satiety. In: Cooper SJ, Iversen SD, Iversen LL, eds. Multiple CCK receptors in the CNS. Oxford: Oxford University Press, 1992:166-82.
28. Smith GP, Gibbs J. Satiating effect of cholecystokinin. Ann N Y Acad Sci 1994;713:236-41.
29. Krief S, Lonnqvist F, Raimbault S, Baude B, Spronsen AV. Arner P, Stresberg AD, Ricquier D, Emorine LJ. Tissue distribution of β3-adrenergic receptor mRNA in man. J Clin Invest 1993;91:344-9.
30. Himms-Hagen J. Brown adipose tissue thermogenesis: interdisciplinary studies. FASEB J 1990;4:2890-8.
31. Collins S, Daniel KW, Rohlfs EM, Ramkumar V, Taylor IL, Gettys TW. Impaired expression and functional activity of the β3-and β1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. Mol Endocrinol 1994;8:518-27.
32. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N, Sorkin JD, Roth J, Shuldiner AR. Time of onset of non-insulin dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N Engl J Med 1995;333:343-7.
33. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the β3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995;333:348-51.
34. Clement K, Vaisse C, Manning BSJ, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD. Genetic variation in the β3-adrenergic receptor and in increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-4.
35. Arner P. The β3-adrenergic receptor - a cause and cure of obesity. N Engl J Med 1995;333:382-3.
36. Ricquier D, Casteill L, Bouillaud F. Molecular studies of the uncoupling protein. FASEB J 1996;5:2237-42.
37. Oppert JM, Vohl MC, Chagnon M, Dionne FT. DNA polymorphism in the uncoupling protein (UCP) gene and human body fat. Int J Obes Relat Metab Disord 1994;18:526-31.
38. Warden CH, Fisler JS. Identification of genes underlying polygenic obesity in animal models. In: Bouchard C, ed. The genetics of obesity. Boca Raton: CRC Press, 1994:181-99.
39. Kwon HY, Bultman SJ, Loffler C, Chen WJ, Furdon PJ, Powell JG, Usala AL, Wilkison W, Hansmann I, Woychik RP. Molecular structure and chromosomal mapping of the human homolog of the agouti gene. Proc Natl Acad Sci USA 1994;91:9760-4.
40. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994;371:799-802.
41. Coleman DL, Elcher EM. Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse. J Hered 1990;81:424-7.
42. Naggert JK, Fricker LD, Varlamov O, Nishina PM, Rouille Y, Steiner DF, Carroll RJ, Paigen BJ, Leiter EH. Hyperproinsulinemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 1995;10:135-42.
43. Rouille Y, Duguay SJ, Lund K, Furuta M, Gong Q, Lipkind G, Oliva AAJr, Chan SJ, Steiner DF. Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: the subtilisin-like proprotein convertases. Front Neuroendocrinol 1995;16:322-61.
44. Ohlemiller KK, Hughes RM, Mosinger-Ogilvie J, Speck JD, Grosof DH, Silverman MS. Cochlear and retinal degeneration in the tubby mouse. Neuroreport 1995;6:845-9.
45. Noben-Trauth K, Naggert JK, North MA, Nishina PM. A candidate gene for the mouse mutation tubby. Nature 1996;380:534-8.
46. Kleyn PW, Fan W, Kovats SG, Lee JJ, Pulido JC, Wu Y, Berkemeier LR, Misumi DJ, Holmgren L, Charlat O, Woolf EA, Tayber O, Brody T, Shu P, Hawkins F, Kennedy B, Baldini L, Ebeling C, Alperin GD, Chen H, Glucksmann-Kuis MA, Carlson GA, Duyk GM, Moore KJ. Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Cell 1996;85:281-90.
47. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered 1950;41:317-8.
48. Coleman DL. Diabetes-obesity syndromes in mice. Diabetes 1982;31(1 Suppl):1-6.
49. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 1973;9:294-8.
50. Chua SC, Chung WK, Wu-Peng XS, Zhang Y, Liu S-M, Tartaglia L, Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996;271:994-6.
51. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
52. Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, Mori K, Tamura N, Hosoda K, Yoshimasa Y, Jingami H, Kawada T, Nakao K. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 1995;44:855-8.
53. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6.
54. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fai Y, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM. Leptin levels in human and rodent: measurement of plasma leptin and Ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-61.
55. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-9.
56. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
57. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Auwerx J. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995;377:527-9.
58. Cusin I, Sainsbury A, Doyle P, Rohner-Jeanrenaud F, Jeanrenaud B. The ob gene and insulin. A relationship leading to clues to the understanding of obesity. Diabetes 1995;44:1467-70.
59. De Vos P, Saladin R, Auwerx J, Staels B. Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 1995;270:15958-61.
60. Trayburn P, Thomas MEA, Duncan JS, Rayner DV. Acute cold-induced suppression of ob (obese) gene expression in white adipose tissue of mice: mediation by the sympathetic system. Biochem J 1995;311:729-31.
61. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A, MacKellar W, Rosteck PR, Schoner B, Smith D, Tinsley FC, Zhang X-Y, Heiman M. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377:530-532.
62. Malik KF, Young WS. Localization of binding sites in the central nervous system for leptin (OB protein) in normal, obese (ob/ob), and diabetic (db/db) C57B1/6J mice. Endocrinology 1996;137:1497-500.
63. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Rchards GJ, Campfield a, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Woolf EA, Monroe CA, Tepper RI. Identification and expression cloning of leptin receptor, Ob-R. Cell 1995;83:1263-71.
64. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-5.
65. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, Friedman JM. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996;379:632-5.
66. McKibbin PE, Cotton SJ, McMillan S, Holloway B, Mayers R, McCarthy HD, Williams G. Altered neuropeptice Y concentrations in specific hypothalamic regions of obese (fa/fa) Zucker rats. Possible relationship to obesity and neuroendocrine disturbances. Diabetes 1991;40:1423-9.
67. Chung WK, Truett GE, Smoller JW, Hirsch J, Leibel RL. Increased hypothalamic preproneuropeptide Y mRNA in six- to nine-day-old fatty (fa/fa) fats. FASEB J 1992;6:A1785.
68. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D Jr, Woods SC, Seeley RJ, Weigle DS. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45:531-5.
69. Considine RV, Considine EL, Williams CJ, Nyce MR, Magosin SA, Bauer TL, Rosato EL, Colberg J, Caro JF. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 1995;95:2986-8.
70. Hamilton BS, Paglia D, Kwan AYM, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995;1(9):953-6.
71. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
72. McGregor GP, Desaga JF, Ehlenz K, Fischer A, Heese F, Hegele A, Lammer C, Peiser C, Lang RE. Radioimmunological measurement of leptin in plasma of obese and diabetic human subjects. Endocrinology 1996;137:1501-4.
73. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, Marco C, Caro JF. Nocturnal rise of leptin in lean, obese, and non-insulin dependent diabetes mellitus subjects. J Clin Invest 1996;97:1344-7.
74. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YDI. Measurement of plasma glucose, free fatty acids, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes 1988;37:1020-4.
75. Clement K, Garner C, Hager J, Philippi A, LeDue C, Carey A, Harris TJR, Jury C, Cardon LR, Basdevant A, Demenais F, Guy-Grand B, North M, Froguel P. Indicaton for linkage of the human OB gene region with extreme obesity. Diabetes 1996;45:687-90.
76. Reed DR, Ding Y, Xu W, Cather C, Green ED, Price RA. Extreme obesity may be linked to markers flanking the human OB gene. Diabetes 1996;45:691-4.
77. Considine RV, Considine EL, Williams CJ, Hyde TM, Caro JF. The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa fat mutations. Diabetes 1996;19:992-4.
78. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996;17:305-11.
79. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D. Cerebrospinal fluid leptin levels; relationship to plasma levels and to adiposity in humans. Nat Med 1996;2:586-93.
80. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang P-L, Sinha MK, Considine RV. Decreased cerebrospial fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996;348:159-61.
81. Bouchard C, Perusse L. Heredity and body fat. Annu Rev Nutr 1988;8:259-77.
82. Donaldson MDC, Chu CE, Cooke A, Wilson A, Greene SA, Stephenson JBP. The Prader-Willi syndrome. Arch Dis Child 1994;70:58-63.
83. Andersson LB. Genes and obesity. Ann Med 1996;28:5-7.